NCT07532148 2026-04-15
Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Chong Kun Dang Pharmaceutical
Phase 1 Not yet recruiting
Chong Kun Dang Pharmaceutical
Roswell Park Cancer Institute
WestVac Biopharma Co., Ltd.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Shanghai Gynecologic Oncology Group
AstraZeneca
Aromics Therapeutics
Zhejiang University